Enamine Ltd., a chemical research organization and producer of novel building blocks and screening libraries, and TBD Biodiscovery, a GMP manufacturer of fine chemicals including chemical active pharmaceutical ingredients (APIs), have entered into a collaboration agreement. The partnership aims to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards utilizing Enamine’s know-how and process development expertise. This will help researchers meet the manufacturing feasibility criteria required for drug candidate selection, providing a rapid and cost effective scaled supply of new compounds.

Enamine says its catalogue of building blocks is one of the largest in the world and has been widely used by pharmaceutical companies for more than 15 years to develop lead compounds and drug candidates. With syntheses of these compounds first realized by Enamine, the company holds specialist knowledge that can be critical to successful scale-up. In the announced collaboration Enamine will optimize synthesis processes while TBD Biodiscovery will use the developed protocols to manufacture requested products to GMP standard.

“We recognize that the building blocks we synthesize are being incorporated into the development of new drugs,” said Dr. Vladimir Ivanov, chief of sales and marketing, Enamine. “We are confident that by working in partnership with TBD Biodiscovery with their extensive experience in providing synthesis services under GMP, we can further extend the support we provide and help streamline the manufacturing process.”

Dr. Andrus Tasa, chairman of the management board, TBD Biodiscovery, said, “I have been very impressed by the creativity of Enamine’s chemists in designing new chemical synthesis. We are happy to have Enamine’s support in optimizing the chemical processes used by us for GMP manufacture.”